Analytical balance with black peppercorns alongside a golden nanoparticle in a lab vial, representing the scientific reassessment of piperine and curcumin delivery

It's Time to Reassess Piperine and Curcumin: The Evidence Doesn't Support What You've Been Told

By Michael Centola, Ph.D. (Google Scholar) & Philip Alex, M.D., Ph.D. (PubMed) — Co-inventors, U.S. patent applications (WO2023023648A1, US20240350660A1, US20240350659A1) for cyclodextrin-based curcumin delivery systems | Haus Bioceuticals Inc.

The most repeated claim in curcumin supplementation, that piperine from black pepper increases curcumin bioavailability by 2,000% [1], has never been independently replicated. In 27 years since the original study was published, 4 research groups across 3 countries tested piperine's effect on curcumin blood levels. None confirmed that piperine increases blood levels of active curcumin [2, 3, 4, 5]. Consistent with the 4 piperine bioavailability studies, the few published clinical trials that compared the clinical effects of curcumin + piperine against curcumin alone found that the addition of piperine either had no effect or was associated with loss of curcumin efficacy and increased side effects [6, 7, 8].

For decades, supplement labels, health blogs, and influencer videos have perpetuated a talking point based on a single unreplicated study with significant methodological limitations [1, 9, 10]. As detailed below, independent research, including pharmacokinetic replication attempts, head-to-head clinical trials, and meta-analyses, tells a very different story.

  • The 2,000% bioavailability claim has never been independently replicated.
  • In head-to-head clinical trials, the addition of piperine either had no effect or was associated with loss of curcumin efficacy and increased side effects.
  • Curcumin + piperine clinical studies lacking curcumin-alone comparators show modest benefits, on par with curcumin-alone research.
  • Piperine's mechanism carries drug interaction risks most labels don't disclose.
  • Solubility-based delivery technology is superior to piperine-based enzyme inhibition.

The 2,000% Bioavailability Claim Has Never Been Independently Replicated

The 1998 Study Used Methods That Couldn't Distinguish Active from Inactive Curcumin

The most cited study in curcumin supplementation comes from Shoba et al., published in Planta Medica in 1998 [1]. In an industry-sponsored trial, healthy volunteers received 2 grams of curcumin with and without 20 mg piperine. Without piperine: serum curcumin was undetectable or very low. With piperine: substantially higher levels in the first hour. The reported increase: 2,000%.

That finding has a critical limitation that wasn't fully appreciated in 1998. The analytical methods used didn't distinguish between free (unconjugated) curcumin, the form that can cross cell membranes and interact with biological targets, and conjugated metabolites (glucuronides and sulfates), which are larger, poorly membrane-permeable, and rapidly cleared by the kidneys. In this study, as in several early curcumin bioavailability studies, samples were treated with enzymes that converted inactive curcumin conjugates, molecules the body had already tagged for elimination, back into parent curcumin before measurement. The reported levels therefore included both active free curcumin and relatively inactive curcumin the body had already metabolized for elimination. A 2019 analytical critique argued this reporting convention can systematically misrepresent circulating free curcumin levels [9]. A 2020 LC-MS study made the point even more directly: using different hydrolysis enzymes on the same plasma sample produced roughly double the "free curcumin" reading, demonstrating the limitations of the methodology used in what is considered a landmark study [10].

Four Independent Labs Tested Piperine. None Confirmed the Original Finding.

Volak et al., 2013 (Tufts University). Eight healthy volunteers received curcumin with and without piperine. No meaningful change in curcumin pharmacokinetics with piperine co-administration [2].

Flory et al., 2021 (Hohenheim University, Germany). Twelve subjects tested in a randomized crossover. Piperine did not increase free curcumin levels. The same study found that formulations designed to improve post-digestive solubility, micelles (~57× higher absorption) and γ-cyclodextrin complexes (~30×), far outperformed native curcumin, while piperine appeared ineffective [3].

Fança-Berthon et al., 2021. Thirty subjects in a pharmacokinetic crossover. Same conclusion: piperine did not significantly increase curcumin blood levels [4].

Kroon et al., 2025 (Amsterdam University Medical Center). An independent crossover study in nine healthy males that specifically measured unconjugated curcumin separately from conjugates. Plasma levels of unconjugated curcumin remained below 2 nanomolar in most conditions, including high-dose curcumin with 20 mg piperine. Piperine did not increase unconjugated or even total plasma levels. The authors explicitly argued that bioavailability claims should be based on unconjugated curcumin, not conjugates [5].

The high-dose failure. A separate study gave healthy men high-dose curcumin in a product containing BioPerine and reported no detectable plasma curcumin at all, and no change in the target biomarker (heme oxygenase-1 expression) [11].

Taken together: piperine's ability to raise biologically active free curcumin has not been replicated by any independent research group since 1998. No regulatory body, not the FDA, not the EMA, would accept a combination trial without a single-agent control as evidence that a specific component is active. That's not a high bar. It's the minimum standard for attributing efficacy to an ingredient.

(Learn how cyclodextrin nanocarrier delivery addresses curcumin's solubility at the molecular level →)

In Head-to-Head Clinical Trials, Piperine Added Nothing or Made Outcomes Worse

Clinical studies comparing the effects of curcumin + piperine vs. curcumin alone are consistent with the pharmacokinetic results. Piperine did not improve curcumin's clinical effects, and in some cases curcumin + piperine had lower activity and was associated with more adverse events than curcumin alone.

Liver disease: curcumin alone outperformed curcumin + piperine. A 2025 meta-analysis of 15 RCTs (905 patients) in nonalcoholic fatty liver disease found that curcumin alone significantly reduced liver enzymes ALT and AST, but curcumin plus piperine showed no significant effect on either marker [6]. A separate meta-analysis confirmed: adding piperine to curcumin did not benefit aminotransferase levels in NAFLD patients [7]. In the one clinical domain where piperine's additive value was directly assessed at the meta-analytic level, piperine didn't help, and may have interfered.

Inflammatory bowel disease: no significant clinical improvement. A 2024 RCT in 51 IBD patients included all three groups: placebo, curcumin alone (1,000 mg/day), and curcumin + piperine (1,000 mg + 10 mg/day) [8]. Neither the curcumin-alone nor the curcumin + piperine group showed significant clinical improvement. The only nominally significant finding, a difference in SOD (p=0.041), does not survive correction for the many comparisons tested (Bonferroni threshold ~p=0.005). Meanwhile, the curcumin + piperine group reported four times more heartburn than the other groups.

In summary, in every published clinical study where piperine's effects have been directly tested against curcumin alone, the addition of piperine either didn't help or made outcomes worse. Unfortunately, the curcumin clinical literature is dominated by industry-sponsored studies that assessed the effects of curcumin + piperine without a curcumin-alone comparator. When these studies demonstrate an effect of the combination, it perpetuates the unsupported narrative that adding piperine to curcumin is necessary, despite the absence of evidence that piperine is contributing anything.

Curcumin + Piperine Clinical Studies Lacking Curcumin-Alone Comparators Show Modest Benefits

Results of Combo on Par with Curcumin-Alone Clinical Studies

Despite the absence of curcumin-alone comparators, placebo-controlled trials of curcumin + piperine are frequently cited as evidence that piperine works. Here's what those trials actually found, and how the results compare to studies of curcumin without piperine.

Multiple meta-analyses confirm that curcumin + piperine can produce statistically significant changes in certain biomarkers in placebo-controlled RCTs: modest reductions in triglycerides and total cholesterol, small improvements in HDL-C, and some effects on inflammatory and oxidative stress markers [12, 13, 14]. The effects are real, strongest in people with existing metabolic conditions, and are frequently cited as evidence that piperine "works."

But separate meta-analyses have assessed the same endpoints using curcumin without piperine. When the effect sizes are placed side by side, curcumin + piperine does not outperform curcumin alone on any major endpoint.

Endpoint Curcumin Alone vs. Placebo Curcumin + Piperine vs. Placebo
Triglycerides −26.2 mg/dL (k=2) [15] −18.6 mg/dL (k=16) [12]
Total cholesterol −13.7 mg/dL (k=2) [15] −6.6 mg/dL (k=16) [12]
LDL cholesterol −16.2 mg/dL (k=2) [15] −2.2 mg/dL, not significant (k=14) [12]
HDL cholesterol (increase) +5.2 mg/dL (k=2) [15] +1.5 mg/dL (k=16) [12]
HbA1c −0.70% [16] −0.34%, not significant [13]
MDA (oxidative damage) Significant reduction [17] Significant reduction [17]
SOD (antioxidant enzyme) Not significant [17] Significant increase [17]

Both columns show effects vs. placebo. k = number of RCTs in the pooled estimate. Lipid data: curcumin-alone subgroup from a formulation-stratified meta-analysis [15]; curcumin + piperine from a dedicated 16-RCT meta-analysis [12]. HbA1c: curcumin in type 2 diabetes [16] vs. curcumin + piperine [13]. Oxidative stress: subgroup analysis (with vs. without piperine) within the same meta-analysis [17]. These comparisons draw from separate meta-analyses of overlapping but not identical trial pools.

The pattern is consistent: across lipids, glycemic control, and inflammation, curcumin + piperine does not produce larger effects than curcumin without piperine. In four of five quantitative comparisons, the curcumin-alone estimate is larger. CRP tells a similar story: curcumin broadly shows significant reductions across multiple meta-analyses, while a GRADE-assessed synthesis specific to curcumin + piperine trials found the CRP reduction was not statistically significant [14]. The one endpoint where a piperine-specific signal has been reported is SOD, an antioxidant enzyme marker where the piperine subgroup showed a significant increase while the non-piperine subgroup did not [17]. However, SOD is a surrogate marker, not a clinical outcome, and the more direct measure of oxidative damage (MDA) decreased with or without piperine. An important caveat: the curcumin-alone lipid subgroup includes only 2 RCTs. But the consistency of the pattern across every endpoint is difficult to dismiss.

Nearly every trial in the curcumin + piperine column compared the combination against a placebo, not against curcumin alone. That design cannot tell you whether piperine is contributing anything. The table suggests it isn't, and the head-to-head NAFLD and IBD data in the previous section confirm it directly.

A 2024 RCT complicates the attribution problem further. When piperine was tested alone, without curcumin, in 68 NAFLD patients, reductions in ALT, AST, triglycerides, cholesterol, and fasting blood glucose were noted compared to placebo [18]. This means some benefits attributed to "curcumin + piperine" in placebo-controlled trials may not be curcumin benefits at all. Piperine may be producing its own metabolic effects that get misattributed to the combination.

While the literature as a whole failed to demonstrate superiority of curcumin + piperine vs. curcumin alone, the field would benefit from additional comparator studies that are adequately powered, placebo controlled, blinded, and conducted in a variety of indications to more completely address whether piperine adds clinical value.

Piperine's Mechanism Carries Risks Most Labels Don't Disclose

Piperine Permanently Disables the Enzyme That Processes Half of All Medications

Piperine's mechanism of action as a bioenhancer, inhibiting CYP3A4 and P-glycoprotein, is the same mechanism that can alter how your body processes medications. A 2019 study in Drug Metabolism and Disposition confirmed piperine is a mechanism-based inactivator of CYP3A4, meaning it permanently disables enzyme molecules until your body produces new ones [19].

A 2024 PBPK modeling study predicted what happens when 20 mg/day piperine, a dose common in curcumin supplements, is taken for 7 days alongside CYP3A4 substrate drugs [20]:

Medication Primary Use Predicted Increase in Drug Exposure
Simvastatin Cholesterol ~59%
Alfentanil Pain management ~39%
Triazolam Sleep / anxiety ~36%
Cyclosporine Immune suppression ~35%
Nifedipine Blood pressure ~34%
Ritonavir Antiviral ~31%

These are modeled predictions, not observed clinical outcomes. Real-world effects depend on dose, duration, and the specific medication. One controlled human study found no meaningful changes in the pharmacokinetics of three probe drugs during short-term exposure [2]. But piperine's mechanism of action, permanently disabling CYP3A4 enzyme molecules, is confirmed, and the modeling predicts clinically meaningful effects at the doses found in standard curcumin supplements taken daily. (See our full FAQ on curcumin safety and drug interactions →)

Independent and Industry-Affiliated Research Tell Different Stories

It is of note that many of the positive RCTs on curcumin + piperine include authors affiliated with piperine ingredient manufacturers. This includes the comprehensive 2023 review [21], the sepsis RCT [26], the stroke rehabilitation trial [27], and several others. Industry-funded trials are common in supplement science, and these were published in peer-reviewed journals and include randomized placebo controlled studies. But non-industry funded independent studies, including the Kroon 2025 pharmacokinetic reappraisal [5] and the NAFLD meta-analyses [6, 7], tend to have less enthusiastic conclusions regarding piperine's contribution. Moreover, as discussed above, the literature as a whole suggests piperine's contribution is questionable.

Solubility-Based Delivery Technology Is Superior to Piperine-Based Enzyme Inhibition

Piperine represents one approach to curcumin's absorption problem: slow down the body's clearance machinery after curcumin is absorbed so more survives in circulation. The approach may be limited, as discussed above, and the trade-off is that the same machinery processes medications, hormones, and other compounds your body needs to regulate precisely [19, 20].

The more modern, and as discussed below, more effective approach uses advanced delivery systems that facilitate curcumin absorption without interfering with metabolic enzymes. These include phospholipid complexes (e.g., Meriva) [28], micelle formulations (e.g., NovaSOL) [3], colloidal nanoparticle dispersions (e.g., Theracurmin) [29], cyclodextrin nanocarrier systems (e.g., NanoCur) [3, 5], solid lipid particles (e.g., Longvida) [30], and amorphous solid dispersions (e.g., curcuRouge) [31], all designed to solve curcumin's poor water solubility through molecular engineering rather than enzyme suppression.

A 2021 randomized, double-blind crossover trial directly compared multiple formulations at the same curcumin dose (207 mg). The results were unambiguous: strategies that improved post-digestive solubility, e.g. micelles (~57× higher absorption) and γ-cyclodextrin complexes (~30×), significantly outperformed piperine-based formulas, which, compared to curcumin alone, appeared to be ineffective in increasing curcumin's bioavailability [3]. The 2025 Kroon reappraisal confirmed the pattern: the micellar formulation achieved the highest plasma levels of any product tested, while piperine added no measurable benefit.

The advantage extends beyond head-to-head pharmacokinetic studies. At the meta-analytic level, a dedicated synthesis of nano-curcumin RCTs (a carrier strategy) reported a fasting blood glucose reduction of −18.1 mg/dL [22], more than three times the −5.9 mg/dL seen in the curcumin + piperine meta-analysis [13]. Nano-curcumin also produced significant improvements in HOMA-IR (insulin resistance), where curcumin + piperine did not. In knee osteoarthritis, a 2025 network meta-analysis found that bioavailability-enhanced curcuminoid preparations were among the top performers for pain and function outcomes compared with placebo [23], while piperine-specific superiority was not established.

An important nuance, curcumin blood levels don't always correlate with its clinical effects. For example, in a controlled human study micellar curcumin dramatically improved curcumin's pharmacokinetics but the higher levels had no measurable impact on inflammatory responses [24]. Moreover, a pharmacokinetic/pharmacodynamic crossover study found weak or no relationship between plasma curcumin levels and tissue concentrations [25]. These studies suggest blood measurements may not capture where curcumin is actually acting.

This is why NanoCur's formulation was optimized based on clinical activity in disease models rather than blood levels. For detailed results, see published patent applications US20240350660A1, US20240350659A1, which demonstrate the robust preclinical activity of NanoCur's 5 nm cyclodextrin nanocarrier.

A comprehensive analysis of advanced curcumin delivery systems is beyond the scope of this article and deserves its own dedicated review. What is clear from the literature is that the head-to-head evidence consistently demonstrates the superiority of molecular engineering approaches over piperine-based enzyme suppression [3, 5].

What to Consider When Choosing a Curcumin Supplement

  • Evidence suggests curcumin + piperine has modest clinical activity, but the benefits may be from the curcumin, not the piperine. Placebo-controlled trials show modest biomarker improvements. But those effect sizes are on par with or smaller than curcumin-alone research, head-to-head trials confirm the pattern, and a piperine-alone RCT suggests some of the benefits may not involve curcumin at all.
  • The industry talking point, '2,000% more bioavailable,' does not hold up under scrutiny. That number likely reflects conjugated metabolites, not the free curcumin your cells can use. Four independent research groups have failed to replicate the finding. When you see bioavailability claims, ask: more of what, exactly?
  • If you take prescription medications, the piperine question is practical, not theoretical. Piperine permanently inactivates CYP3A4, a liver enzyme that processes roughly half of all prescription medications. This is a conversation to have with a healthcare provider, especially for statins, calcium channel blockers, immunosuppressants, benzodiazepines, or antivirals.
  • Advanced delivery technologies have outperformed piperine in head-to-head testing. Solubility-based formulations achieved 30–57× higher curcumin absorption in a controlled crossover trial, while piperine appeared ineffective. These approaches work by engineering the molecule for better absorption rather than suppressing your body's enzyme systems.
  • Look for independent testing and independent research. Third-party lab verification confirms what's on the label is in the bottle. Independent clinical and pharmacokinetic research, not funded by the ingredient manufacturer, provides the most reliable evidence of efficacy. (See what independent testing looks like →)

(New to curcumin? Start here: Curcumin vs. Turmeric — What's the Difference →)

Frequently Asked Questions

Does black pepper really increase curcumin absorption?

It depends on what "absorption" means and how it's measured. The famous 1998 study reported a 20-fold increase in total serum curcumin, but the analytical methods used could not distinguish between free (active) curcumin and conjugated metabolites the body had already tagged for elimination. Four independent research groups (2013–2025) have since tested piperine's effect on curcumin blood levels using modern analytical methods, and none replicated the original finding. The most recent, from Amsterdam UMC in 2025, specifically measured unconjugated curcumin and found piperine had no effect.

Does curcumin + piperine have real clinical benefits?

Some placebo-controlled trials show modest improvements in inflammatory markers, oxidative stress markers, triglycerides, and fasting blood glucose, strongest in people with existing metabolic conditions. However, these studies overwhelmingly compare the combination against a placebo, not against curcumin alone. When meta-analytic effect sizes for curcumin + piperine are compared against separate curcumin-alone meta-analyses, the combination does not produce larger effects on any major endpoint. In the clinical domains where piperine's additive value was directly assessed in head-to-head trials (NAFLD liver enzymes and IBD), curcumin alone outperformed or matched the combination, while the piperine group reported more side effects. A separate RCT testing piperine alone found it produced metabolic improvements without curcumin, raising questions about what is actually driving the benefits seen in combination trials.

Is "2,000% more bioavailable" the same as "more effective"?

No. Bioavailability measures how much of a compound reaches the bloodstream. It doesn't tell you whether it produces meaningful health effects. The 2,000% number has not been independently replicated and likely reflects conjugated metabolites with limited biological activity, not free curcumin. Moreover, research shows that even dramatically higher blood levels don't always translate to stronger clinical effects — curcumin blood levels don't reliably correlate with tissue concentrations or clinical outcomes.

Is piperine safe?

Piperine is widely consumed in food and generally well tolerated. At concentrated supplement doses (5–20 mg/day), it permanently inactivates CYP3A4, a liver enzyme that processes roughly half of all prescription medications. A 2024 modeling study predicted meaningful increases in drug exposure for simvastatin (+59%), cyclosporine (+35%), and other common medications at standard supplement doses. People on prescription medications should discuss piperine-containing supplements with a healthcare provider.

Do I need piperine if I'm using a modern curcumin delivery system?

No. Advanced delivery technologies — including phospholipid complexes (Meriva), micelle formulations (NovaSOL), colloidal nanoparticle dispersions (Theracurmin), and cyclodextrin nanocarriers (NanoCur) — improve curcumin absorption through molecular engineering rather than enzyme inhibition. In the Flory 2021 crossover trial, solubility-based formulations achieved 30–57× higher absorption than native curcumin, while piperine appeared ineffective. The Kroon 2025 reappraisal confirmed the pattern. These approaches work without suppressing the enzyme systems your body uses to process medications.

Why do most curcumin supplements still contain piperine?

Piperine (as BioPerine) is inexpensive, well-known to consumers, and backed by published research, most of which was conducted in collaboration with the ingredient manufacturer. It's the oldest established bioenhancement approach. Newer delivery technologies require more sophisticated manufacturing, but the head-to-head evidence consistently demonstrates their superiority, and they avoid the enzyme-inhibition trade-offs that come with piperine.

Should I stop taking a curcumin supplement that contains BioPerine?

That's a conversation for your healthcare provider. If you're healthy and not on medications, the drug-interaction risk is less relevant, though the bioavailability question remains: independent research suggests piperine may not be increasing free curcumin levels at all. If you take daily medications metabolized by CYP3A4, a piperine-free formulation is worth discussing.

The Bottom Line

The most repeated claim in curcumin supplementation, that black pepper piperine dramatically boosts curcumin's effectiveness, is not supported by the independent scientific evidence. Four research groups across three countries have failed to replicate piperine's effect on curcumin blood levels since 1998. In the clinical domains where piperine's additive value was directly tested against curcumin alone, it either didn't help or made outcomes worse. And piperine's mechanism of action as a bioenhancer, enzyme inhibition, creates real drug-interaction risk for the millions of people taking daily medications.

Placebo-controlled trials do show modest biomarker improvements for the combination. But when those effect sizes are compared against curcumin-alone research, the combination does not produce larger effects on any major endpoint. Head-to-head trials confirm the pattern, and a piperine-alone RCT suggests some benefits may not involve curcumin at all. The field would benefit from additional comparator studies to more completely address whether piperine adds clinical value. Until then, the 2,000% bioavailability claim should be treated as what it is: an unreplicated finding from 1998.

The most important insight from the growing body of curcumin research isn't a simple verdict on piperine. It's that the delivery problem in curcumin supplementation is real, the solution matters, and how a supplement solves it, by suppressing your liver enzymes or by engineering the molecule itself, is as important as the milligrams on the label.

NanoCur uses patented cyclodextrin nanocarrier technology to deliver pharmaceutical-grade curcumin optimized for clinical activity, not just bioavailability. Piperine-free. Eurofins verified. Learn how it works → · Try NanoCur →

References

  1. Shoba G, et al. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 1998;64(4):353-356. PMID: 9619120
  2. Volak LP, et al. Effect of a herbal supplement containing curcumin and piperine on midazolam, flurbiprofen, and paracetamol pharmacokinetics in healthy volunteers. Br J Clin Pharmacol. 2013;75(2):450-462. PMC3579260
  3. Flory S, et al. Increasing post-digestive solubility of curcumin is the most successful strategy to improve its oral bioavailability: a randomized cross-over trial in healthy adults and in vitro bioaccessibility experiments. Mol Nutr Food Res. 2021;65(24):e2100613. doi:10.1002/mnfr.202100613
  4. Fança-Berthon P, et al. Pharmacokinetics of a single dose of turmeric curcuminoids depends on formulation: results of a human crossover study. J Nutr. 2021;151(7):1802-1816. doi:10.1093/jn/nxab087
  5. Kroon MAGM, et al. A pharmacokinetic study and critical reappraisal of curcumin formulations enhancing bioavailability. iScience. 2025;28:112575. doi:10.1016/j.isci.2025.112575
  6. Vajdi AA, et al. Curcumin supplementation and liver enzymes in NAFLD: a systematic review and meta-analysis of 15 RCTs. Nutr Rev. 2025;82(12):1845-1863. doi:10.1093/nutrit/nuad166
  7. Aragón-Vela J, et al. Effects of curcumin and curcumin plus piperine on NAFLD: a meta-analysis of RCTs. Phytother Res. 2024;38(8):4049-4065. doi:10.1002/ptr.8274
  8. Martins ASDP, et al. Effect of curcumin plus piperine on redox imbalance, fecal calprotectin and cytokine levels in IBD patients: a randomized controlled trial. Pharmaceuticals. 2024;17(7):849. doi:10.3390/ph17070849
  9. Stohs SJ, et al. A review of bioavailability studies of curcumin. J Agric Food Chem. 2019. PMID: 31684927
  10. Luis PB, et al. Incomplete hydrolysis of curcumin conjugates by β-glucuronidase: detection of complex conjugates in plasma. Mol Nutr Food Res. 2020;64(6):e1901037. PMID: 31962379
  11. Klickovic U, et al. Human pharmacokinetics of high-dose curcumin with BioPerine: no detectable plasma curcumin. Br J Clin Pharmacol. 2014;78(6):1382-1387. PMC3925623
  12. Karimi M, et al. Co-supplementation of curcuminoids and piperine on lipid profile: a meta-analysis of 16 RCTs. Lipids. 2025. doi:10.1002/lipd.70004
  13. Karimi M, et al. Effect of curcumin plus piperine co-supplementation on glycemic control in adults: a meta-analysis of randomized controlled trials. J Diabetes Metab Disord. 2025. doi:10.1007/s40200-025-01799-y
  14. Karimi M, et al. Co-supplementation of curcuminoids and piperine on liver enzymes and inflammatory biomarkers: a systematic review and meta-analysis. Food Sci Nutr. 2025. doi:10.1002/fsn3.70588
  15. Epelde F, et al. Effects of turmeric supplementation on lipid profile in adults with cardiometabolic risk: a formulation-stratified meta-analysis. Pharmaceutics. 2025;17(12):1609. doi:10.3390/pharmaceutics17121609
  16. Zhang T, et al. Curcumin and glycemic control in type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. 2021. PMC8410384
  17. Tabrizi R, et al. The effects of curcumin-containing supplements on biomarkers of inflammation and oxidative stress: a systematic review and meta-analysis of randomized controlled trials. Phytother Res. 2019;33(2):253-262. PMC6855189
  18. Nouri-Vaskeh M, et al. Effects of piperine supplementation on liver enzymes, lipid profile, and glycemic markers in NAFLD: a randomized controlled trial. Sci Rep. 2024. PMC10782007
  19. Cui T, et al. Piperine is a mechanism-based inactivator of CYP3A. Drug Metab Dispos. 2019;47(12):1376-1385. doi:10.1124/dmd.119.088955
  20. Lin F, et al. Predicting food-drug interactions between piperine and CYP3A4 substrate drugs using PBPK modeling. Int J Mol Sci. 2024;25(20):10955. doi:10.3390/ijms252010955
  21. Heidari H, et al. Curcumin-piperine co-supplementation and human health: a comprehensive review of preclinical and clinical studies. Phytother Res. 2023;37(4):1462-1487. doi:10.1002/ptr.7737
  22. Ashtary-Larky D, et al. Effects of nano-curcumin supplementation on cardiovascular risk factors: a systematic review and meta-analysis of clinical trials. Complement Ther Med. 2021. PMC8300831
  23. Wai HS, et al. Turmeric and curcuminoids for knee osteoarthritis: a network meta-analysis of randomized controlled trials. BMC Complement Med Ther. 2025;25:45. doi:10.1186/s12906-025-05045-z
  24. Schulze J, et al. Micellar curcumin: pharmacokinetics and effects on inflammatory markers in healthy volunteers. Mol Nutr Food Res. 2022;66(22):e2200214. PMID: 36101515
  25. Asher GN, et al. Randomized pharmacokinetic crossover study comparing two curcumin preparations in plasma and rectal tissue of healthy human volunteers. J Clin Pharmacol. 2017;57(2):185-193. PMC5233601
  26. Alikiaii B, et al. Therapeutic effects of curcumin and piperine combination in critically ill patients with sepsis: a randomized double-blind controlled trial. Trials. 2025;26:205. doi:10.1186/s13063-025-08916-5
  27. Boshagh K, et al. The effect of curcumin supplementation on cardiovascular risk factors and antioxidant capacity in chronic stroke patients: a randomized double-blind controlled trial. Nutr J. 2023;22:55. doi:10.1186/s12937-023-00905-1
  28. Cuomo J, et al. Comparative absorption of a standardized curcuminoid mixture and its lecithin formulation. J Nat Prod. 2011;74(4):664-669. PMID: 21413691
  29. Sasaki H, et al. Innovative preparation of curcumin for improved oral bioavailability. Biol Pharm Bull. 2011;34(5):660-665. PMID: 21532153
  30. Gota VS, et al. Safety and pharmacokinetics of a solid lipid curcumin particle formulation in osteosarcoma patients and healthy volunteers. J Agric Food Chem. 2010;58(4):2095-2099. PMID: 20092313
  31. Sunagawa Y, et al. A novel solvent-free co-grinding preparation improves curcumin bioavailability in healthy volunteers: a single-center crossover study. J Funct Foods. 2023;100:105385. PMC9852671

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Back to blog